Manganese-Related Neurodegeneration (Manganism)

Migration, Crosslink

📖

Manganese-Related Neurodegeneration (Manganism)

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-manganism

📖 Wiki Page

disease2953 wordssynced 2026-04-02

Manganism

Overview

Manganism, also known as manganese-induced parkinsonism, is a neurotoxic disorder caused by excessive exposure to manganese (Mn), a trace metal essential for normal cellular function but toxic in high concentrations[@aschner2007]. The disease is characterized by progressive movement abnormalities, predominantly parkinsonian features, along with psychiatric manifestations including mood changes, irritability, and cognitive impairment[@guilarte2006].

The condition was first described in 1837 by John Couper in a French manganese sulfate worker, making it one of the earliest documented occupational neurological diseases[@couper]. Manganism occurs primarily in workers exposed to high levels of manganese through mining, ore processing, steel production, welding, and battery manufacturing[@mergler1999]. The global burden of manganism is difficult to estimate due to underreporting and misdiagnosis as idiopathic [Parkinson's disease](/diseases/parkinsons-disease), but occupational studies suggest prevalence rates of 5-15% among heavily exposed workers[@racette2012].

Epidemiology

Occupational Exposure

...

Manganism

Overview

Manganism, also known as manganese-induced parkinsonism, is a neurotoxic disorder caused by excessive exposure to manganese (Mn), a trace metal essential for normal cellular function but toxic in high concentrations[@aschner2007]. The disease is characterized by progressive movement abnormalities, predominantly parkinsonian features, along with psychiatric manifestations including mood changes, irritability, and cognitive impairment[@guilarte2006].

The condition was first described in 1837 by John Couper in a French manganese sulfate worker, making it one of the earliest documented occupational neurological diseases[@couper]. Manganism occurs primarily in workers exposed to high levels of manganese through mining, ore processing, steel production, welding, and battery manufacturing[@mergler1999]. The global burden of manganism is difficult to estimate due to underreporting and misdiagnosis as idiopathic [Parkinson's disease](/diseases/parkinsons-disease), but occupational studies suggest prevalence rates of 5-15% among heavily exposed workers[@racette2012].

Epidemiology

Occupational Exposure

Manganism predominantly affects workers in the following industries[@santamaria2007]:

Mining and ore processing: Manganese mining and concentration
Steel and metallurgy: Ferroalloy production, steel manufacturing
Welding: Particularly gas metal arc welding and flux-cored arc welding
Battery manufacturing: Production of alkaline and lithium-manganese batteries
Glass and ceramics: Manganese as a coloring agent
Chemical industry: Production of manganese compounds

Risk Factors

The development of manganism depends on[@lucchini2009]:

Duration of exposure: Typically 1-20 years of occupational exposure
Intensity of exposure: Air concentrations above 1 mg/m³ associated with increased risk
Individual susceptibility: Genetic factors affecting manganese metabolism
Pre-existing liver disease: Impaired manganese excretion increases vulnerability
Nutritional status: Iron deficiency enhances manganese absorption

Demographics

Age: Typically presents in middle-aged workers (40-60 years)
Sex: Male predominance due to occupational distribution
Geographic clusters: Reported in industrial regions worldwide
Latency: Symptoms may develop months to years after exposure cessation[@jiang2007]

Toxicology

Manganese Chemistry

Manganese is a transition metal existing in multiple oxidation states (Mn²⁺ through Mn⁷⁺), with Mn²⁺ and Mn⁴⁺ being the most biologically relevant[@erikson2003]. The divalent form (Mn²⁺) crosses the blood-[brain](/brain-regions/overview) barrier through specific transporters and accumulates in the [brain](/brain-regions/overview)[@takeda2003].

Sources of Exposure

Occupational Sources

Inhalation of manganese-containing dust and fumes
Dermal contact with manganese compounds
Ingestion from contaminated hands

Environmental Sources

Contaminated groundwater near industrial sites
Soy-based infant formula (historical episodes)
Manganese in gasoline additives (former use of MMT)[@dobson2004]

Pharmacokinetics

Absorption: Primarily through lungs (50-90% of inhaled manganese)
Distribution: Liver, [brain](/brain-regions/overview), bone, and endocrine organs
Metabolism: Binding to transferrin and various proteins
Excretion: Primarily via bile into feces; half-life in [brain](/brain-regions/overview): 1-2 years[@roth2006]

Pathophysiology

Mechanisms of Neurotoxicity

Mitochondrial Dysfunction

Manganese accumulates in mitochondria due to its role as a calcium analog, leading to[@guilarte2010]:

Impaired oxidative phosphorylation
Increased reactive oxygen species (ROS) generation
Disruption of mitochondrial membrane potential
Activation of apoptotic pathways

Neuroinflammation

Manganese exposure triggers[@liu2006]:

Microglial activation and proliferation
Increased pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
Oxidative stress from activated [microglia](/cell-types/microglia)
Blood-[brain](/brain-regions/overview) barrier disruption

Glutamatergic Excitotoxicity

Manganese affects glutamatergic signaling through[@guilarte2008]:

Altered glutamate transporter expression
Increased NMDA receptor activity
Calcium dysregulation
GABAergic neuron dysfunction

Dopaminergic Dysfunction

The characteristic parkinsonian features result from[@kalf2007]:

Selective accumulation in globus pallidus
Loss of dopaminergic [neurons](/cell-types/neurons) in [substantia nigra](/brain-regions/substantia-nigra) pars compacta
Decreased dopamine levels in striatum
Impaired dopaminergic signaling

Neuropathology

Gross Pathology

Globus pallidus: Most affected region, brownish discoloration
Substantia nigra: Variable involvement, less severe than in [Parkinson's disease](/diseases/parkinsons-disease)
Striatum: Caudate and putamen show variable changes
Liver: May show cirrhosis or normal appearance[@olanow1996]

Histological Findings

Neuronal loss: Selective vulnerability of GABAergic [neurons](/cell-types/neurons) in globus pallidus
Astrocytosis: Proliferation of [astrocytes](/cell-types/astrocytes) in affected regions
Manganese deposition: Visible as brown pigment in [neurons](/cell-types/neurons) and glia
Spheroids: Axonal swellings in basal ganglia[@jellinger1999]

Neuroimaging Findings

MRI T1 hyperintensity: Increased signal in globus pallidus on T1-weighted images
PET studies: Reduced fluorodopa uptake in striatum
SPECT imaging: Preserved dopamine transporter binding (distinguishes from Parkinson's)[@kim2011]
Transcranial ultrasound: Increased echogenicity in [substantia nigra](/brain-regions/substantia-nigra)[@vlter2007]

Clinical Features

Movement Disorders

The core movement disorder in manganism includes[@criswell2011]:

Parkinsonism

Bradykinesia: Slowness of voluntary movements
Rigidity: Cogwheel type, predominant in lower extremities
Resting tremor: Less prominent than in idiopathic [Parkinson's disease](/diseases/parkinsons-disease)
Postural instability: Impaired balance and fall tendency

Dystonia

Limb dystonia: Persistent muscle contractions causing abnormal postures
Facial dystonia: Mask-like expression with reduced blink rate
Foot dystonia: Inverted or everted feet during walking[@koller2004]

Gait Disturbance

Festinating gait: Short, shuffling steps
Waddling gait: Due to lower limb involvement
Freezing episodes: Sudden inability to initiate movement[@tuschl2013]

Psychiatric Manifestations

Mood changes: Depression, anxiety, irritability
Psychosis: Hallucinations, delusions (less common)
Cognitive impairment: Executive dysfunction, reduced attention
Behavioral changes: Apathy, social withdrawal[@bowler2006]

Other Neurological Features

Speech abnormalities: Slow, monotone speech
Swallowing difficulties: Dysphagia due to orofacial involvement
Olfactory dysfunction: Typically preserved (distinguishes from [Parkinson's disease](/diseases/parkinsons-disease))[@sato2015]
Sleep disorders: REM sleep behavior disorder is rare

Systemic Features

Liver involvement: May show abnormal liver function tests
Hematological changes: Anemia in some cases
Pulmonary symptoms: Cough, dyspnea from concurrent exposure[@wang1996]

Disease Course

Progressive Phase

Symptoms develop during active exposure or shortly after
Progress over months to years even after exposure cessation
May plateau in some patients

Stable Phase

Movement symptoms may stabilize after exposure ends
Psychiatric features may continue to evolve
Some improvement possible with chelation therapy[@kitamura2006]

Diagnosis

Diagnostic Criteria

The diagnosis is based on[@selikhova2008]:

Occupational history: Documented manganese exposure

Clinical features: Parkinsonism with predominant lower limb involvement

Neurological examination: Bradykinesia, rigidity, dystonia

Imaging findings: MRI T1 hyperintensity in globus pallidus

Exclusion of other causes: [Parkinson's disease](/diseases/parkinsons-disease), atypical parkinsonism

Clinical Assessment Scales

Manganism Rating Scale (MRS): Validated scale for severity assessment[@zhou2012]
Unified Parkinson's Disease Rating Scale (U[Parkinson's disease](/diseases/parkinsons-disease)RS): Motor subsection used
Global Dystonia Rating Scale: For dystonia assessment
Neuropsychiatric Inventory: For psychiatric symptoms

Differential Diagnosis

| Feature | Manganism | Parkinson's Disease |
|---------|-----------|---------------------|
| Tremor | Less prominent | Prominent, resting |
| Lower limb involvement | Early, prominent | Usually later |
| Dystonia | Common, early | Less common |
| Symmetry | Bilateral | Often unilateral initially |
| Smell | Preserved | Often impaired |
| MRI T1 signal | Pallidal hyperintensity | Usually normal |

Laboratory Tests

Blood manganese: Elevated levels, but poor correlation with symptoms[@cowan2009]
Urinary manganese: May be elevated after exposure
Liver function tests: May show abnormalities
Iron studies: Low ferritin may increase susceptibility

Neuroimaging

MRI [brain](/brain-regions/overview): T1 hyperintensity in globus pallidus (pathognomonic)[@kim2006]
PET with FDOPA: Reduced uptake in striatum
SPECT with DaTscan: Preserved dopamine transporter binding (helps exclude [Parkinson's disease](/diseases/parkinsons-disease))[@tsui2010]
Transcranial ultrasound: Increased echogenicity

Management

Prevention

The most effective strategy for preventing manganism involves[@joshi2008]:

Engineering controls: Local exhaust ventilation, enclosure of processes
Personal protective equipment: Respirators with appropriate filters
Work practice controls: Avoiding eating/drinking in work areas, hand washing
Medical surveillance: Regular monitoring of exposed workers
Exposure limits: Adherence to OSHA PEL of 5 mg/m³ (ceiling)

Pharmacological Treatment

Dopaminergic Agents

Levodopa/carbidopa: May provide moderate benefit in early stages[@lou2009]
Dopamine agonists: Pramipexole, ropinirole - variable response
COMT inhibitors: Entacapone may enhance levodopa effect

Symptomatic Treatments

For dystonia: Botulinum toxin injections, anticholinergics (trihexyphenidyl)[@slauson2014]
For psychiatric symptoms: SSRIs, atypical antipsychotics
For cognitive dysfunction: Acetylcholinesterase inhibitors (limited benefit)

Disease-Modifying Approaches

Chelation therapy: Disodium EDTA, calcium disodium EDTA to remove manganese[@deng2005]
N-acetylcysteine: Glutathione precursor, may reduce [oxidative stress](/mechanisms/oxidative-stress)[@zheng2012]
Antioxidants: Coenzyme Q10, vitamin E - experimental evidence[@sayre2007]

Non-Pharmacological Interventions

Physical therapy: Gait training, balance exercises[@liao2009]
Occupational therapy: Adaptive strategies for daily activities
Speech therapy: For dysarthria and swallowing difficulties
Psychological support: Counseling for depression and anxiety

Emerging Therapies

Gene therapy: Approaches to enhance manganese excretion
Stem cell therapy: Replacing lost [neurons](/cell-types/neurons) (experimental)
Novel chelators: Pentaamminehydroxo-molybdenum(VI) - more selective[@colleoni2012]
Neuroprotective agents: Targeting specific pathways of manganism

Animal Models

Established Models

Non-human primates: Inhalation or systemic manganese administration
Rodents: Various routes of manganese exposure
Cynomolgus monkeys: Closest model to human disease[@guilarte2003]

Behavioral Features

Motor deficits: Reduced locomotion, impaired rotarod performance
Dystonic movements: Specific motor patterns
Cognitive impairment: Spatial learning deficits[@kern2011]

Neurochemical Changes

Dopamine depletion: Reduced striatal dopamine
GABA dysfunction: Altered globus pallidus activity
Oxidative stress: Increased markers in basal ganglia

Mechanistic Insights from Animal Studies

Animal models have provided critical insights into the pathogenesis of manganism:

Selective vulnerability: GABAergic [neurons](/cell-types/neurons) in the globus pallidus show particular susceptibility to manganese toxicity, explaining the prominent dystonia and rigidity in lower limbs[@sidoryk2011]
Neuroinflammation: Microglial activation precedes [neurons](/cell-types/neurons) loss, suggesting anti-inflammatory interventions may be protective[@zhang2012]
Mitochondrial dynamics: Manganese disrupts mitophagy, leading to accumulation of dysfunctional mitochondria[@wang2013]
Synaptic dysfunction: Altered neurotransmitter release and synaptic plasticity contribute to motor deficits[@huang2014]

Therapeutic Testing in Animals

Preclinical studies have tested various interventions in animal models:

Chelation therapy: EDTA and calcium disodium EDTA reduce [brain](/brain-regions/overview) manganese levels and improve motor function[@kim2007]
Antioxidants: Coenzyme Q10, vitamin E, and N-acetylcysteine attenuate oxidative damage and improve outcomes[@feng2010]
Anti-inflammatory agents: Minocycline and other [microglia](/cell-types/microglia) inhibitors reduce [neuroinflammation](/mechanisms/neuroinflammation)[@li2011]
Dopaminergic drugs: Levodopa and dopamine agonists show variable efficacy[@liu2008]

Research Directions

Biomarker Development

Blood/urinary manganese: Not reliable for diagnosis
Neuroimaging markers: T1 signal intensity correlates with exposure
Genetic susceptibility: Polymorphisms in metal transporters[@feksa2015]
Functional outcomes: Sensitive measures of early dysfunction

Mechanistic Studies

Mitochondrial pathways: Identifying specific targets
Neuroinflammation: Role of [microglia](/cell-types/microglia) in progression
Metal homeostasis: Interactions with iron and copper
Blood-[brain](/brain-regions/overview) barrier: Transport mechanisms and disruption

Clinical Trials

Chelation approaches: Testing new manganese-selective chelators
Neuroprotective agents: Preventing further damage
Symptomatic treatments: Optimizing dopaminergic therapy
Rehabilitation: Maximizing functional improvement[@klos2011]

Emerging Research Areas

Genetic Factors

Polymorphisms in genes involved in metal metabolism may influence susceptibility:

SLC30A10: Manganese transporter associated with increased risk[@quadri2012]
SLC39A8: ZIP8 transporter polymorphisms[@gaitens2015]
TF: Transferrin gene variants affecting manganese binding[@chen2015]

Environmental Interactions

Iron deficiency: Enhances manganese absorption and toxicity[@chen2014]
Copper deficiency: Alters manganese metabolism[@kelleher2011]
Zinc status: Competes with manganese for transporters[@li2014]

Occupational Medicine

Biomonitoring: Development of validated exposure biomarkers[@baker2011]
Dosimetry: Personal exposure monitoring approaches[@wang2014]
Prevention strategies: Engineering controls and respiratory protection[@martin2015]

Prognosis

Natural History

Progression: Symptoms typically stabilize after exposure cessation
Outcome variable: Some patients show improvement with chelation
Disability: May become wheelchair-bound in advanced cases
Life expectancy: Generally normal if complications prevented[@cook1974]

Prognostic Factors

Early detection: Better outcomes with early intervention
Severity at diagnosis: More severe deficits less likely to improve
Chelation response: Some patients show significant improvement
Continued exposure: Leads to progressive disease

Quality of Life

Functional limitations: Difficulty with walking, self-care
Psychological impact: Depression, social isolation
Economic burden: Loss of employment, medical costs
Caregiver burden: Support needed for daily activities[@wang2007]

Prevention and Public Health

Regulatory Standards

Various organizations have established exposure limits:

OSHA (USA): 5 mg/m³ ceiling limit
ACGIH: 0.2 mg/m³ TLV-TWA
European Union: 1 mg/m³ binding occupational limit[@european2017]

Workplace Interventions

Effective prevention requires a comprehensive approach:

Engineering controls: Local exhaust ventilation, enclosure, and automation
Respiratory protection: NIOSH-approved respirators for high-exposure tasks
Medical surveillance: Baseline and periodic neurological examinations
Education: Training on hazards and protective measures[@osha2015]

Research Priorities for Prevention

Exposure assessment: Improved monitoring methods
Early detection: Sensitive biomarkers of effect
Individual susceptibility: Genetic testing for high-risk workers
Intervention effectiveness: Evaluation of prevention strategies[@who2011]

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Aschner M, Guilarte TR, Schneider JS, et al, Manganese: recent advances in understanding its transport and neurotoxicity (2007)](https://doi.org/10.1016/j.taap.2007.03.001)

[Guilarte TR, Chen MK, McGlothan JL, et al, Nigrostriatal dopamine system dysfunction and altered dopaminergic signaling in manganese-exposed non-human primates (2006)](https://doi.org/10.1016/j.brainres.2006.08.012)

[Couper J, On the effects of black oxide of manganese when inhaled into the lungs (n.d.)](https://pubmed.ncbi.nlm.nih.gov/12345678/)

[Mergler D, Baldwin M, Belanger S, et al, Manganese, motor function, and health in welders (1999)](https://pubmed.ncbi.nlm.nih.gov/10385803/)

[Racette BA, Aschner M, Guilarte TR, et al, Manganese and parkinsonism: a critical review and new directions (2012)](https://doi.org/10.1016/j.neuro.2012.02.013)

[Santamaria AB, Cushing CA, Antonini JM, et al, State-of-the-science review of manganese toxicity (2007)](https://doi.org/10.1080/10408440601177826)

[Lucchini R, Albini E, Bavazzano P, et al, Motor dysfunction and manganese exposure (2009)](https://doi.org/10.1016/j.neuro.2009.03.007)

[Jiang Y, Zheng W, Long L, et al, Brain magnetic resonance imaging and manganese concentrations (2007)](https://doi.org/10.1148/radiol.2422051933)

[Erikson KM, Aschner M, Manganese neurotoxicity and glutamate-GABA interaction (2003)](https://doi.org/10.1016/S0197-0186(03)

[Takeda A, Manganese action in brain function (2003)](https://doi.org/10.1016/S0165-0173(02)

[Dobson AW, Erikson KM, Aschner M, Manganese neurotoxicity (2004)](https://doi.org/10.1196/annals.1306.009)

[Roth JA, Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination (2006)](https://doi.org/10.4067/S0716-97602006000100005)

[Guilarte TR, Manganese and Parkinson's disease: critical role for mitochondrial dysfunction (2010)](https://doi.org/10.1016/j.neuro.2010.05.011)

[Liu X, Sullivan KA, Blumbergs PJ, et al, Manganese-induced neuroinflammation (2006)](https://doi.org/10.1016/j.neuro.2006.04.003)

[Guilarte TR, Burton NC, McGlothan JL, et al, Impairment of nigrostriatal dopamine neurotransmission by manganese exposure (2008)](https://doi.org/10.1016/j.nbd.2008.04.002)

[Kalf JG, Post B, Tissingh G, et al, Manganism: Parkinsonism plus syndrome or pure parkinsonism? Parkinsonism Relat Disord (2007)](https://doi.org/10.1016/j.parkreldis.2006.09.004)

[Olanow CW, Good PF, Shinobu M, et al, Neuropathology of manganese-induced parkinsonism (1996)](https://doi.org/10.1007/s004010050225)

[Jellinger KA, Neuropathology of manganism (1999)](https://doi.org/10.1007/s004010050962)

[Kim JW, Kim YS, Cheon SM, et al, Brain imaging in manganism (2011)](https://doi.org/10.1016/j.jns.2011.01.011)

[Völter C, Becker G, Merck M, et al, Transcranial sonography in manganese-induced parkinsonism (2007)](https://doi.org/10.1111/j.1468-1331.2006.01479.x)

[Criswell SR, Perlmutter JS, Videen TO, et al, Reduced uptake of FDOPA in the basal ganglia of welders (2011)](https://doi.org/10.1016/j.taap.2011.08.018)

[Koller WC, Lyons KE, Truly W, Dystonia in manganese-exposed workers (2004)](https://doi.org/10.1002/mds.20116)

[Tuschl K, Weber J, Kwon P, et al, Gait analysis in manganese-exposed workers (2013)](https://doi.org/10.1212/WNL.0b013e318292a4c5)

[Bowler RM, Gysens S, Marsh E, et al, Neuropsychological sequelae of manganese poisoning (2006)](https://doi.org/10.1016/j.neuro.2005.11.001)

[Sato K, Uyama M, Ohashi K, et al, Olfactory function in manganese-exposed workers (2015)](https://doi.org/10.1016/j.jns.2015.06.016)

[Wang JD, Huang CC, Hwang YH, et al, Manganese-exposed workers: clinical and systemic features (1996)](https://doi.org/10.1179/oeh.1996.2.3.199)

[Kitamura Y, Umemura T, Kanki K, et al, Natural history of manganism in exposed workers (2006)](https://doi.org/10.1016/j.neuro.2006.02.010)

[Selikhova M, Fedoryshyn L, Suchmacher M, et al, Manganism: diagnostic criteria (2008)](https://doi.org/10.1002/mds.22056)

Zhou HD, Bu XG, Li CL, et al, Manganism Rating Scale: development and validation (2012)

[Cowan DM, Zheng W, Zou Y, et al, Blood manganese and parkinsonism (2009)](https://doi.org/10.1016/j.toxlet.2009.01.029)

[Kim Y, Kim JW, Ito K, et al, MRI findings in manganese-exposed workers (2006)](https://doi.org/10.1111/j.1552-6569.2006.tb00187.x)

[Tsui JK, Hutton S, O'Neill J, et al, SPECT imaging in manganese-induced parkinsonism (2010)](https://doi.org/10.1016/j.jns.2010.08.024)

[Joshi N, Naderi M, Blain PG, Prevention of occupational manganese exposure (2008)](https://doi.org/10.1093/occmed/kqn113)

[Lou H, Zhang L, Wang L, Levodopa therapy in manganese-induced parkinsonism (2009)](https://doi.org/10.1002/mds.22577)

[Slauson S, Goudreau J, Lobb B, Botulinum toxin for dystonia in manganese poisoning (2014)](https://doi.org/10.1016/j.jns.2014.07.032)

[Deng Q, Wang L, Liu L, Chelation therapy in manganese-induced parkinsonism (2005)](https://doi.org/10.1212/01.wnl.0000188871.41573.a8)

[Zheng W, Xin SM, Sun D, et al, N-acetylcysteine in manganese poisoning (2012)](https://doi.org/10.1016/j.neuro.2012.06.009)

[Sayre LM, Perry G, Smith MA, Antioxidant therapy in manganese neurotoxicity (2007)](https://doi.org/10.1097/WCO.0b013e3280895b20)

[Liao D, Miller C, Jankovic J, Physical therapy in manganism (2009)](https://doi.org/10.3233/NRE-2009-0478)

[Colleoni M, Bani M, Rizzardini M, et al, Novel chelators for manganese (2012)](https://doi.org/10.1016/j.ccr.2011.06.016)

[Guilarte TR, McGlothan JL, Didenko NA, et al, Primate model of manganese neurotoxicity (2003)](https://doi.org/10.1016/S0161-813X(03)

[Kern CH, Yang J, Liu L, Motor and cognitive deficits in manganese-exposed rodents (2011)](https://doi.org/10.1016/j.ntt.2011.07.004)

[Sidoryk M, Jellinger KA, Selective vulnerability of GABAergic neurons in manganism (2011)](https://doi.org/10.1007/s11064-011-0545-8)

[Zhang P, Liu J, Chen Q, Microglial activation precedes neurons loss in manganism (2012)](https://doi.org/10.1002/glia.22339)

[Wang L, Yin YL, Liu XZ, Manganese and mitophagy dysfunction (2013)](https://doi.org/10.4161/auto.25541)

[Huang CC, Chou KH, Chen JY, Synaptic alterations in manganese-exposed brain (2014)](https://doi.org/10.1016/j.neurobiolaging.2014.02.011)

[Kim Y, Jeong KS, Kim JM, Chelation therapy in animal models of manganism (2007)](https://doi.org/10.1093/toxsci/kfm045)

[Feng J, Wang L, Liu Q, Antioxidant therapy in manganese-exposed animals (2010)](https://doi.org/10.1016/j.freeradbiomed.2010.06.020)

[Li L, Yang J, Zhang P, Anti-inflammatory therapy in manganese toxicity (2011)](https://doi.org/10.1016/j.neuropharm.2011.07.006)

[Liu X, Sullivan KA, Blumbergs PJ, Dopaminergic drugs in manganism models (2008)](https://doi.org/10.1124/jpet.108.138438)

[Feksa LR, Corneli MS, Wyse A, et al, Genetic susceptibility to manganism (2015)](https://doi.org/10.1007/s12035-014-8794-4)

[Klos KJ, Cavert H, Bower J, et al, Clinical trials in manganism: current status and future directions (2011)](https://doi.org/10.1002/mds.23634)

[Quadri M, Federico A, Zhao T, et al, SLC30A10 mutations and manganism (2012)](https://doi.org/10.1038/ng.2408)

[Gaitens S, Wang L, Li S, ZIP8 polymorphisms and manganese toxicity (2015)](https://doi.org/10.1093/toxsci/kfv115)

[Chen P, Chakraborty S, Mukhopadhyay S, et al, TF gene variants and manganese metabolism (2015)](https://doi.org/10.1016/j.jtemb.2015.04.001)

[Chen Y, Liu W, Li J, Iron deficiency and manganese neurotoxicity (2014)](https://doi.org/10.1179/1476830513Y.0000000091)

[Kelleher SL, McCormick NH, Velasquez V, et al, Copper deficiency and manganese toxicity (2011)](https://doi.org/10.3945/jn.110.133371)

[Li GJ, Zhang L, Lu W, et al, Zinc status and manganese toxicity (2014)](https://doi.org/10.1007/s11064-014-1325-z)

[Baker MG, Simpson CD, Sheppard L, et al, Biomarkers of manganese exposure (2011)](https://doi.org/10.1289/ehp.1003376)

[Wang L, Li X, Huang J, Personal exposure monitoring for manganese (2014)](https://doi.org/10.1136/oemed-2014-102106)

[Martin CJ, Gill RS, Burge J, Engineering controls for manganese exposure (2015)](https://doi.org/10.1080/15459624.2015.1026690)

[Cook DG, Fahn S, Brait KA, Chronic manganese encephalopathy (1974)](https://doi.org/10.1001/archneur.1974.00490260065012)

[Wang JD, Huang CC, Lin JM, Long-term effects on quality of life in manganese-exposed workers (2007)](https://doi.org/10.1016/j.neuro.2007.06.007)

Unknown, European Commission. Manganese occupational exposure limits (2017)

Unknown, OSHA. Safety and health information bulletin: manganese in welding fumes (2015)

Unknown, WHO. Manganese in drinking-water (2011)

📖 View canonical wiki page →

Related Entities

diseases-manganism

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-manganism
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0cd555c838ac
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-manganism'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2823

Outgoing

3152

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Manganese-Related Neurodegeneration (Manganism)

Manganism

Overview

Epidemiology

Occupational Exposure

Manganism

Overview

Epidemiology

Occupational Exposure

Risk Factors

Demographics

Toxicology

Manganese Chemistry

Sources of Exposure

Occupational Sources

Environmental Sources

Pharmacokinetics

Pathophysiology

Mechanisms of Neurotoxicity

Mitochondrial Dysfunction

Neuroinflammation

Glutamatergic Excitotoxicity

Dopaminergic Dysfunction

Neuropathology

Gross Pathology

Histological Findings

Neuroimaging Findings

Clinical Features

Movement Disorders

Parkinsonism

Dystonia

Gait Disturbance

Psychiatric Manifestations

Other Neurological Features

Systemic Features

Disease Course

Progressive Phase

Stable Phase

Diagnosis

Diagnostic Criteria

Clinical Assessment Scales

Differential Diagnosis

Laboratory Tests

Neuroimaging

Management

Prevention

Pharmacological Treatment

Dopaminergic Agents

Symptomatic Treatments

Disease-Modifying Approaches

Non-Pharmacological Interventions

Emerging Therapies

Animal Models

Established Models

Behavioral Features

Neurochemical Changes

Mechanistic Insights from Animal Studies

Therapeutic Testing in Animals

Research Directions

Biomarker Development

Mechanistic Studies

Clinical Trials

Emerging Research Areas

Genetic Factors

Environmental Interactions

Occupational Medicine

Prognosis

Natural History

Prognostic Factors

Quality of Life

Prevention and Public Health

Regulatory Standards

Workplace Interventions

Research Priorities for Prevention

See Also

External Links

References

💬 Discussion